Omega Therapeutics (NASDAQ:OMGA) specializes in harnessing the power of genomic programming to develop a new class of DNA-sequence-targeting, mRNA-expressing therapies with the objective of revolutionizing the treatment across multiple disease areas. Their projects primarily focus on leveraging their proprietary Omega Epigenomic Programming™ platform to precisely tune gene expression, without altering the native DNA sequence, facilitating the development of therapies aimed at a broad range of diseases including oncology, regenerative medicine, and autoimmune diseases. Omega aims to pioneer a new era of genomic medicine, with the goal of unlocking the full potential of the human genome to conquer diseases at their genetic roots.